trihexyphenidyl has been researched along with Scleroderma, Systemic in 2 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| ROBINSON, HM | 1 |
| CORDERO, AA | 1 |
| CORTI, RN | 1 |
2 other studies available for trihexyphenidyl and Scleroderma, Systemic
| Article | Year |
|---|---|
Artane in the treatment of morphea and scleroderma; a preliminary report.
Topics: Humans; Scleroderma, Localized; Scleroderma, Systemic; Trihexyphenidyl | 1952 |
[Artane in the treatment of scleroderma].
Topics: Humans; Scleroderma, Systemic; Trihexyphenidyl | 1953 |